Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benchmark anti-cMET ADC (vcMMAE)
- Development stage
- Preclinical
- Lead developer
- Mythic Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A protease-cleavable antibody-drug conjugate (ADC) targeting cMET, utilized as a preclinical benchmark by Mythic Therapeutics. It consists of a clinical-stage anti-cMET antibody conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) via a valine-citrulline (vc) linker. This compound is an in-house recreation of telisotuzumab vedotin (ABBV-399) and is used to evaluate the efficacy and payload delivery of novel cMET-targeted therapies, such as MYTX-011, in models of non-small cell lung cancer (NSCLC) and other cMET-expressing solid tumors.
- Other names
- anti-cMET vcMMAE ADCbenchmark ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on benchmark anti-cMET ADC (vcMMAE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benchmark anti-cMET ADC (vcMMAE).